Oncology Brothers: Practice-Changing Cancer Discussions Advancements and Challenges in Metastatic Colorectal Cancer Treatment
Dec 21, 2025
The podcast dives into the latest advances in treating metastatic colorectal cancer. Key discussions highlight the significance of next-generation sequencing and biomarker testing in treatment decisions. Second-line options like TAS-102, Regorafenib, and Fruquintinib are explored along with crucial clinical trial data. The conversation also covers managing side effects and improving patient quality of life. Insights from the STELLAR-303 study reveal new perspectives on immunotherapy, setting the stage for better treatment strategies.
AI Snips
Chapters
Transcript
Episode notes
Test With NGS Before Choosing First-Line
- Upfront comprehensive NGS and biomarker testing drives first-line therapy decisions in mCRC.
- When no actionable mutations exist, sequencing second-line options becomes essential for outcomes.
Use Every-Other-Week TAS-102 Dosing
- Use TAS-102 on an every-other-week schedule to improve tolerability based on Kathy Yang's study.
- Follow regimen as five days on (days 1–5) rather than prolonged dosing to limit toxicity.
Step-Up Regorafenib To Reduce Toxicity
- Start regorafenib with step-up dosing per ReDOS to reduce toxicity.
- Escalate from 80 mg to 120 mg then to 160 mg rather than starting at full dose.